Vivici boosts whey protein titers 30% with Enduro Genetics technology

A 30% lift in whey-protein titers is the kind of number that matters when the conversation shifts from proving precision fermentation can make dairy proteins to proving it can make them cheaply enough, at scale. Vivici said Enduro Genetics’ Enduro Sense technology increased production titers and yields in its beta-lactoglobulin process within five months, from tech transfer to full bioreactor validation, without changing the existing process setup or using more feedstock.

That is why this update lands as a manufacturing story, not a lab curiosity. In fermentation-based proteins, yield sits close to the center of the economics: higher titers can mean better plant utilization, fewer batches needed for the same output, and a lower implied cost per kilo if downstream recovery keeps pace. For a company like Vivici, which is trying to move animal-free whey into real food and beverage formats, that matters more than a clean technical win on its own.

Vivici is a joint venture backed by Fonterra and DSM-Firmenich, and its flagship ingredient, Vivitein BLG, is a nature-equivalent beta-lactoglobulin made by microbial fermentation. The company publicly launched the ingredient on February 26, 2025, after saying in February 2024 that it had self-affirmed GRAS status in the United States, making it commercially available to customers there. That commercial footing makes the 30% gain more consequential, because the question is no longer whether the protein can be made, but how efficiently it can be produced often enough to support broader adoption.

Vivici has positioned Vivitein BLG for functional foods, sports nutrition, meal replacements, and high-protein beverage formats, and it introduced a compact protein shots concept at Newtopia Now 2025 on July 9, 2025. In 2026, the company has been targeting clear drinks and protein-shot applications, where solubility, clarity, and taste can decide whether a formulation works at all. A more productive strain does not solve every bottleneck, but it helps narrow the gap between promising ingredient and dependable supply.

Christian Munch, Enduro Genetics’ chief executive, said the technology can “unlock the biomanufacturing industry from just being focused on specialty products to more everyday products.” That is the real test here. If the 30% gain holds at commercial scale, it could improve the economics enough to move precision-fermented whey closer to mainstream beverage, bar, and recovery products. If it does not, it is still progress, but only the kind that makes an already promising platform somewhat better.